<?xml version="1.0" encoding="UTF-8"?>
<article>
<line>Detection and Characterization </line><line>of Cellular Immune Responses </line><line>Using Peptide–MHC Microarrays </line><line>Yoav Soen<sup>1</sup><sup>[</sup>, Daniel S. Chen<sup>2</sup><sup>,</sup><sup>5</sup><sup>[</sup>, Daniel L. Kraft<sup>3</sup>, Mark M. Davis<sup>4</sup><sup>,</sup><sup>5</sup><sup>*</sup>, Patrick O. Brown<sup>1</sup><sup>,</sup><sup>5</sup><sup>*</sup> </line><line>1 Department of Biochemistry, Stanford University, Stanford, California, United States of America, 2 Department of Internal Medicine, Division of Oncology, Stanford </line><line>University, Stanford, California, United States of America, 3 Department of Pediatrics, Division of Bone Marrow Transplant, Stanford University, Stanford, California, United </line><line>States of America, 4 Department of Microbiology and Immunology, Stanford University, Stanford, California, United States of America, 5 Howard Hughes Medical Institute, </line><line>Stanford University, Stanford, California, United States of America </line><line>The detection and characterization of antigen-specific T cell populations is critical for understanding the development </line><line>and physiology of the immune system and its responses in health and disease. We have developed and tested a </line><line>method that uses arrays of peptide–MHC complexes for the rapid identification, isolation, activation, and </line><line>characterization of multiple antigen-specific populations of T cells. CD4<sup>þ</sup> or CD8<sup>þ</sup> lymphocytes can be captured in </line><line>accordance with their ligand specificity using an array of peptide–MHC complexes printed on a film-coated glass </line><line>surface. We have characterized the specificity and sensitivity of a peptide–MHC array using labeled lymphocytes from T </line><line>cell receptor transgenic mice. In addition, we were able to use the array to detect a rare population of antigen-specific </line><line>T cells following vaccination of a normal mouse. This approach should be useful for epitope discovery, as well as for </line><line>characterization and analysis of multiple epitope-specific T cell populations during immune responses associated with </line><line>viral and bacterial infection, cancer, autoimmunity, and vaccination. </line><line>Introduction </line><line>Antigen-specific cellular immune responses are mediated </line><line>by a diverse population of T cells, each capable of recognizing </line><line>a specific peptide bound to a particular major histocompat- </line><line>ibility complex (MHC) molecule on the surface of host cells. </line><line>Recognition of peptides bound to class I or class II MHC </line><line>molecules leads to the clonal expansion, activation, and </line><line>maturation of T lymphocytes, resulting in effector popula- </line><line>tions of either cytotoxic (CD8þ CTL) or helper (CD4þ) T cells, </line><line>respectively. The presence of antigen-specific effector cells is </line><line>diagnostic of an immune response specific to that antigen; </line><line>detection of these antigen-specific cells is therefore critical </line><line>for the characterization of the response and for under- </line><line>standing its natural course. In addition, a systematic survey of </line><line>the global repertoire of T cell specificities, its dynamics over </line><line>time and between individuals, could be of great value in </line><line>elucidating the inner workings of the immune system and for </line><line>designing efficient strategies for immunization, immunother- </line><line>apy, and treatment of autoimmune disease. </line><line>The development of peptide–MHC tetramers (Altman et al. </line><line>1996) and dimers (Greten et al. 1998) has allowed visualization </line><line>of antigen-specific T cells by flow cytometry and, more </line><line>recently, in situ (Haanen et al. 2000) approaches. This has led </line><line>to characterization of T cell responses to specific antigens </line><line>associated with microbial pathogens (Callan et al. 1998; Ogg </line><line>et al. 1998a; Smith et al. 2000), autoimmunity (Ogg et al. </line><line>1998b), allergens (Seneviratne et al. 2002), and cancer cells </line><line>(Lee et al. 1999; Molldrem et al. 2000). Unfortunately, while a </line><line>significant improvement over previous approaches, the use of </line><line>multimeric soluble peptide–MHC constructs in flow cytom- </line><line>etry is technically difficult, time consuming, expensive, and, </line><line>most importantly, limited to only one or a very few antigen </line><line>specificities at a time. cDNA-based expression libraries and </line><line>various forms of combinatorial synthetic peptide libraries, </line><line>such as the positional scanning combinatorial library (Pinilla </line><line>et al., 1994; Ignatowicz et al. 1996) and bead-bound libraries </line><line>(Hiemstra et al. 1997, 1998a, 1998b), have also been utilized in </line><line>attempts to study T cell receptor (TCR) specificity and </line><line>reactivity. However, these approaches have been hampered </line><line>by the intrinsic limitations of indirect readouts, such as </line><line>proliferation assays, and by the complexity of the libraries, </line><line>which do not allow for the direct visualization of T cell </line><line>interactions with diverse, but individually distinguishable, </line><line>antigens presented by an MHC complex. Consequently, the </line><line>various peptide library approaches are mainly effective when </line><line>used in combination with relatively homogeneous T cell </line><line>populations, such as T cell clones. </line><line>Here we report the development of a cellular array-based </line><line>screening strategy using microarrays of immobilized peptide– </line><line>MHC complexes. This approach is very rapid and allows the </line><line>simultaneous identification, isolation, characterization, and </line><line>Received August 21, 2003; Accepted October 5, 2003; Published December 22, </line><line>2003 </line><line>DOI: 10.1371/journal/pbio.0000065 </line><line>Copyright: NO_UNICODE2003 Soen et al. This is an open-access article distributed under </line><line>the terms of the Creative Commons Attribution License, which permits </line><line>unrestricted use, distribution, and reproduction in any medium, provided the </line><line>original work is properly cited. </line><line>Abbreviations: BSP, BirA substrate peptide; CTL, cytotoxic T lymphocyte; DIC, </line><line>differential interference contrast; FACS, fluorescence-activated cell sorting; FCS, </line><line>fetal calf serum; FITC, fluorescein isothiocyanate; HLA, human leucocyte antigen; </line><line>LCMV, lymphocytic choriomengingitis virus; mAb, monoclonal antibody; MCC, </line><line>moth cytochrome C; MHC, major histocompatibility complex; OVA, ovalbumin; PBS, </line><line>phosphate-buffered saline; PE, phycoerythrin; SA, streptavidin; TCR, T cell receptor; </line><line>TRP, tyrosinase-related protein </line><line>Academic Editor: Philippa Marrack, National Jewish Medical and Research Center </line><line>*To whom correspondence should be addressed. E-mail: mdavis@pmgm2.stanford. </line><line>edu (MMD), pbrown@cmgm.stanford.edu (POB) </line><line>[<sub>T</sub><sub>h</sub><sub>e</sub><sub>s</sub><sub>e</sub> <sub>a</sub><sub>u</sub><sub>t</sub><sub>h</sub><sub>o</sub><sub>r</sub><sub>s</sub> <sub>c</sub><sub>o</sub><sub>n</sub><sub>t</sub><sub>r</sub><sub>i</sub><sub>b</sub><sub>u</sub><sub>t</sub><sub>e</sub><sub>d</sub> <sub>e</sub><sub>q</sub><sub>u</sub><sub>a</sub><sub>l</sub><sub>l</sub><sub>y</sub> <sub>t</sub><sub>o</sub> <sub>t</sub><sub>h</sub><sub>i</sub><sub>s</sub> <sub>w</sub><sub>o</sub><sub>r</sub><sub>k</sub><sub>.</sub> </line><line>PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 429 </line><line>PL<sup>o</sup>S<sub>B</sub><sub>I</sub><sub>O</sub><sub>L</sub><sub>O</sub><sub>G</sub><sub>Y</sub> </line><line>activation of multiple antigen-specific populations of T cells. </line><line>Antigen-specific cells are captured onto an array of individ- </line><line>ual spots of peptide–MHC complexes, with cell capture at </line><line>each spot being dependent on T cell specificity. We </line><line>investigated the specificity of binding and the limit of </line><line>detection achievable by this method, using differentially </line><line>labeled CD8þ and CD4þ T cells of defined specificity from </line><line>transgenic mice. We also found that T cell activation, upon </line><line>binding to the appropriate peptide–MHC on the array, could </line><line>be detected by visualizing a transient increase in intracellular </line><line>calcium. Finally, we have applied this method to detect a </line><line>weak, specific immune response in a normal mouse following </line><line>subcutaneous vaccination with ovalbumin (OVA). The sensi- </line><line>tivity and specificity of this approach, together with the </line><line>ability to survey a large number of specificities quickly and </line><line>easily, may provide a practical way to detect and screen for </line><line>natural immune responses and to characterize variations in </line><line>the T cell repertoire in healthy individuals and in a wide </line><line>variety of disease states. </line><line>Results </line><line>Construction of a Peptide–MHC Array </line><line>Detection of antigen-specific T cells using arrays of </line><line>peptide–MHC complexes was tested. We prepared phycoer- </line><line>ythrin (PE)-labeled peptide–MHC tetramers with the MHC </line><line>class I (H-2k<sup>b</sup>) murine antigen OVA and MHC class II (I-E<sup>k</sup>) </line><line>murine antigen moth cytochrome C (MCC), as described </line><line>(Altman et al. 1996). Both tetramers were validated by </line><line>fluorescence-activated cell sorting (FACS) analysis using </line><line>OVA-specific T cells isolated from OT-1 TCR transgenic </line><line>mice (Hogquist et al. 1994) and MCC-specific 5c.c7 TCR </line><line>transgenic mice (Fazekas de St. Groth et al. 1993), respec- </line><line>tively. To facilitate a comparison between peptide–MHC- </line><line>mediated and antibody-mediated binding, the OVA and MCC </line><line>tetramers were arrayed along with antibodies against several </line><line>mouse lymphocyte cell surface antigens. Hence, individual </line><line>MHC tetramers and several monoclonal antibodies (mAbs) </line><line>were prepared in a 384-well plate at various concentrations </line><line>and dispensed in triplicate onto polyacrylamide film-coated </line><line>glass slides. The latter were determined to be inert for cell </line><line>binding while having a high capacity for protein deposition </line><line>with relatively high fidelity, as compared with a derivatized </line><line>glass slide (aldehyde-, Poly-L-Lysine-, and nitrocellulose- </line><line>coated slides were tested). </line><line>MHC tetramers and antibodies were arrayed using a piezo- </line><line>electric noncontact arrayer, which minimizes film disruption </line><line>and allows control over spot size and the quantity of material </line><line>deposited, by enabling multiple nanoliter-scale drops to be </line><line>deposited onto each spot. The resulting spot size with ten 0.45 </line><line>nl drops (dispensed at a concentration of 1lg/ll) was </line><line>approximately 400 lm in diameter. Each spot of this size </line><line>could accommodate approximately 1,600 closely packed T </line><line>cells. Suspended cells were subsequently layered onto the </line><line>array and were allowed to interact with the predispensed </line><line>tetramers and antibodies (Figure 1A). Following a short </line><line>period of incubation, the slide was washed to remove </line><line>unbound cells and visualized by direct inspection, differential </line><line>interference contrast (DIC), or fluorescence microscopy. </line><line>Inspection by eye revealed tight, nearly confluent cell clusters </line><line>on both the antibody and the MHC tetramer spots (Figure </line><line>1B). </line><line>To optimize the conditions for specific cell capture, we </line><line>investigated the relationship between the surface density of </line><line>the peptide–MHC complexes and the number of bound cells </line><line>(a detailed example is described in Supporting Information; </line><line>see, as part of this example, Figure S1). For a sufficiently </line><line>dense tetramer concentration, we found that the binding of </line><line>OT-1 cells to spots of OVA/K<sup>b</sup> tetramer (OVA peptide 258– </line><line>265, H-2K<sup>b</sup> class I MHC molecule, b<sub>2</sub>-microglobulin) or 5c.c7 </line><line>cells to MCC/E<sup>k</sup> tetramer (MCC peptide 88–103, I-E<sup>k</sup> class II </line><line>MHC molecule, b<sub>2</sub>-microglobulin) was as efficient as the </line><line>binding to spots of mAbs specific to cell surface markers, and </line><line>for a sufficiently dense cell suspension, confluent cell binding </line><line>to the OVA/K<sup>b</sup> tetramer could be achieved with 0.4–0.8 ng of </line><line>OVA/K<sup>b</sup> tetramer per spot (corresponding to a spotting </line><line>solution concentration of 0.1–0.2 mg/ml). </line><line>Identification and Isolation of Antigen-Specific Cytotoxic </line><line>(CD8<sup>þ</sup>) and Helper (CD4<sup>þ</sup>) T Cells </line><line>We tested the specificity of binding to individual spots by </line><line>using pure populations of differentially labeled, antigen- </line><line>specific CTLs and helper T cells from transgenic mice. </line><line>Antigen-specific lymphocytes from OT-1 and 5c.c7 transgenic </line><line>mice were activated and expanded by adding 1 lM OVA and </line><line>MCC peptides to the respective single-cell suspensions on day </line><line>0, and IL-2 (30 U/ml) was supplemented on day 1. On day 7, </line><line>active OT-1 (CD8þ) and 5c.c7 (CD4þ) lymphocytes were </line><line>labeled with DiO or DiD–lipophilic tracers, respectively. </line><line>The two differentially labeled lymphocyte suspensions were </line><line>mixed in a 1:1 ratio and coincubated on the peptide–MHC </line><line>array. Following a 10-min incubation at 208C, the array was </line><line>washed twice in RPMI medium and examined by fluorescence </line><line>microscopy (Figure 2). While anti-CD3 and anti-CD28 mAb </line><line>spots captured both lymphocyte populations, the arrayed </line><line>MCC/E<sup>k</sup> and OVA/K<sup>b</sup> tetramers exclusively captured the </line><line>MCC-specific (red) and OVA-specific (green) cells, respec- </line><line>tively. The nearly complete segregation of OT-1 and 5c.c7 </line><line>cells on the appropriate spots illustrates the highly specific </line><line>nature of lymphocyte capture and the feasibility of array- </line><line>based T cell sorting and analysis. </line><line>Detection of Antigen-Specific T Cells in Complex Cell </line><line>Populations Using a Peptide–MHC Array </line><line>To directly assess the feasibility of detecting rare T cell </line><line>specificities in a complex population, we prepared synthetic </line><line>mixtures of differentially labeled, antigen-specific CTLs and </line><line>T helper cells, diluted with syngeneic wild-type lymph node </line><line>cells (Figure 3A) or splenocytes (Figure 3B). DiD-labeled OT-1 </line><line>cells were diluted 1:100 (Figure 3A, top panels) and 1:1,000 </line><line>(bottom panels) in DiO-labeled C57BL/6 mouse lymph node </line><line>cells that had been depleted of monocytes using anti-CD11b </line><line>beads (to remove cells capable of peptide-independent </line><line>binding to the MHC complex). OT-1 cells of 2.7 310<sup>4</sup> (Figure </line><line>3A, top panels) and 4.41 3 10<sup>3</sup> (Figure 3A, bottom panels) </line><line>were mixed with 2.7 310<sup>6</sup> and 4.41 310<sup>6</sup> of CD11b-depleted </line><line>lymph node cells, respectively. The two different mixtures </line><line>were then separately incubated with identical peptide–MHC </line><line>arrays, each printed with OVA/K<sup>b</sup> tetramer, LCMV/K<sup>d</sup> control </line><line>tetramer (lymphocytic choriomengingitis virus gp peptide </line><line>33–41, H-2K<sup>d</sup> class I MHC molecule, b<sub>2</sub>-microglobulin), MCC/ </line><line>E<sup>k</sup> tetramer, and three different antibody spots ( mouse anti- </line><line>CD8, mouse anti-CD4, and mouse anti-CD28). Following a </line><line>10–30 min incubation at 208C or 378C (similar results were </line><line>PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 430 </line><line>Cellular Peptide–MHC Microarrays </line><line>obtained), the cells were washed twice in RPMI and the slide </line><line>was scanned. </line><line>As expected, the resulting differential binding pattern was </line><line>primarily dictated by antigen specificity even in the presence </line><line>of a very large excess of nonspecific cells in the suspension. In </line><line>particular, the preferential binding of a sufficient number of </line><line>OT-1 cells to the OVA tetramer (on both top and bottom </line><line>panels in Figure 3A), together with the absence of OT-1 </line><line>binding to the LCMV tetramer, demonstrates the feasibility </line><line>of detecting as few as 0.1% of antigen-specific T cells. </line><line>Increasing the total cell number (10-fold increase is easily </line><line>achieved) and using CD8þ instead of CD11bNO_UNICODE selection should </line><line>lead to further improvement in sensitivity (data not shown). </line><line>To test our ability to detect rare T helper cells specific for a </line><line>selected peptide–class II MHC, DiD-labeled 5c.c7 MCC- </line><line>specific lymphocytes were diluted to 1% abundance in </line><line>syngeneic, DiO-labeled B10A splenocytes (Figure 3B) and </line><line>incubated at 378C for 10 min. Despite the low percentage of </line><line>5c.c7 lymphocytes in the mixture (as reflected by the binding </line><line>to the anti-CD28 spot in the bottom right panel of Figure 3B), </line><line>many cells were bound to the MCC/E<sup>k</sup> spots and almost all of </line><line>them were indeed found to be 5c.c7 cells (Figure 3B, right). In </line><line>a control experiment on a duplicate array without the 5c.c7 </line><line>cells, none of the splenocytes adhered to the MCC spots. </line><line>Taken together, these results show that both class I and II </line><line>peptide–MHC complexes can be used to detect rare T cell </line><line>specificities in a complex cell population. </line><line>Detection of a Rare OVA-Specific T Cell Population in </line><line>Vaccinated C57BL/6 Mice </line><line>An important potential application of this technology is in </line><line>systematically monitoring the T cell repertoire in vivo and its </line><line>response to immunization, infection, and other stimuli. We </line><line>tested the feasibility of detecting a weak immune response by </line><line>monitoring the response of C57BL/6 mice to vaccination with </line><line>OVA (Figure 4). CD8þ lymphocytes (2 3 10<sup>6</sup> and 3.2 3 10<sup>6</sup>) </line><line>from the OVA-vaccinated and mock-vaccinated mice, re- </line><line>spectively, were incubated separately with duplicate peptide– </line><line>MHC arrays (on the same slide) containing OVA/k<sup>b</sup> tetramer, <sub>L</sub><sub>C</sub><sub>M</sub><sub>V</sub><sub>/</sub><sub>k</sub><sub>d</sub> <sub>(</sub><sub>c</sub><sub>o</sub><sub>n</sub><sub>t</sub><sub>r</sub><sub>o</sub><sub>l</sub><sub>)</sub> <sub>t</sub><sub>e</sub><sub>t</sub><sub>r</sub><sub>a</sub><sub>m</sub><sub>e</sub><sub>r</sub><sub>,</sub> <sub>a</sub><sub>n</sub><sub>d</sub> <sub>v</sub><sub>a</sub><sub>r</sub><sub>i</sub><sub>o</sub><sub>u</sub><sub>s</sub> <sub>a</sub><sub>n</sub><sub>t</sub><sub>i</sub><sub>b</sub><sub>o</sub><sub>d</sub><sub>i</sub><sub>e</sub><sub>s</sub><sub>.</sub> <sub>T</sub><sub>h</sub><sub>e</sub> </line><line>arrays were incubated at room temperature for 30 min and </line><line>then washed with RPMI to remove free-floating cells. The </line><line>cells were also analyzed by flow cytometry after staining with </line><line>anti-CD8–fluorescein isothiocyanate (FITC) mAb and OVA/k<sup>b</sup> </line><line>Figure 1. A Cellular Microarray </line><line>(A) A schematic diagram illustrating T cell binding to its cognate peptide–MHC spot via peptide–MHC–TCR interactions (not drawn to scale). </line><line>(B) Cells immobilized on the cellular microarray are immediately visible to inspection. When cell coverage exceeds approximately 20% </line><line>confluency, the cluster becomes visible to the naked eye. Shown are cell clusters bound to several triplicate spots of either peptide–MHC </line><line>complexes or antibodies. The image was taken using a digital camera. The arrows and legends indicate the locations and identities of each of the </line><line>printed triplicates. Spot diameter and interspot distance are about 400 lm and 700 lm, respectively. Scale bar is 1.4 mm in length. </line><line>DOI: 10.1371/journal/pbio.0000065.g001 </line><line>Figure 2. Specificity of Lymphocyte Immobilization by Peptide–MHC </line><line>Arrays </line><line>Prelabeled, OVA-specific OT-1 (green) and MCC-specific 5c.c7 (red) </line><line>lymphocytes (6 310<sup>5</sup>) </line><line>were mixed at a 1:1 ratio and added to the </line><line>preprinted peptide–MHC array. While anti-CD3 and anti-CD28 mAb </line><line>spots (left and right top panels) immobilize both lymphocyte </line><line>populations, the OVA and MCC tetramers (left and right bottom </line><line>panels) capture only the OVA-specific and MCC-specific cells, </line><line>respectively. Cells were labeled with DiO and DiD lipophilic tracers </line><line>that incorporate into the cell membrane and do not affect the </line><line>specificity of cell capture. The printed peptide–MHC tetramer spots </line><line>contain the fluorescent dye, which allows visualization of peptide– </line><line>MHC spot borders (data not shown). </line><line>DOI: 10.1371/journal/pbio.0000065.g002 </line><line>PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 431 </line><line>Cellular Peptide–MHC Microarrays </line><line>streptavidin (SA)–PE tetramer. FACS analysis revealed that a </line><line>small fraction (0.27%) of the CTLs from the vaccinated </line><line>mouse are OVA-specific, whereas the control mouse did not </line><line>exhibit an OVA-specific response (Figure 4B). A small but </line><line>significant number of cells from the OVA-vaccinated mouse </line><line>were captured on the OVA/K<sup>b</sup> spots, while none were bound </line><line>by the LCMV/K<sup>d</sup> tetramer spot (Figure 4A). Cells from the </line><line>mock-vaccinated mouse did not bind to either of the </line><line>peptide–MHC tetramers. These results demonstrate that </line><line>these arrays can provide a way to detect even very weak </line><line>immune responses in normal mice. The ability to use this </line><line>approach to detect postvaccination populations of peptide- </line><line>specific T cells in wild-type immune responses has been </line><line>further confirmed with different peptide–MHC systems </line><line>(unpublished data). </line><line>Specific Activation of Lymphocytes Bound to a Peptide– </line><line>MHC Array Spot </line><line>The ability to observe highly specific interactions between </line><line>live lymphocytes and arrays of proteins raises the possibility </line><line>of conducting systematic parallel studies of responses to </line><line>diverse signals arrayed on the surface. We therefore tested </line><line>the possibility of using a protein array to investigate dynamic </line><line>responses of lymphocytes to diverse signals, including specific </line><line>peptide–MHC complexes and other receptor-specific binding </line><line>molecules. OT-1 lymphocytes were loaded with the calcium- </line><line>sensitive dye Fura-2 and were subsequently exposed to an </line><line>MHC array containing OVA/K<sup>b</sup>, LCMV/K<sup>d</sup>, MCC/E<sup>k</sup>, anti-CD3, </line><line>anti-CD28, and anti-CD3/anti-CD28 spots. Throughout the </line><line>experiment, the array was kept at 378C and 5% CO<sub>2</sub>, and </line><line>intracellular calcium levels were monitored every 30 s by </line><line>measuring the ratio of the fluorescence intensity at 340 nm </line><line>and 380 nm. Binding of OT-1 lymphocytes to the OVA/K<sup>b</sup>, </line><line>anti-CD3, and anti-CD3/anti-CD28 MHC array spots, but not </line><line>to LCMV/K<sup>d</sup>, MCC/E<sup>k</sup>, </line><line>or anti-CD28, led to transient spikes in </line><line>intracellular calcium levels (Figure 5). </line><line>Discussion </line><line>Cellular immune responses to pathogens, allergens, de- </line><line>regulated or mutated proteins, and self-antigens play critical </line><line>roles in health and disease. The ability of T cells to respond to </line><line>the immense diversity of possible targets relies on the </line><line>corresponding diversity of the repertoire of TCRs that can </line><line>Figure 3. Sensitivity of Peptide–MHC Tetramer-Mediated Detection of OVA-Specific CTLs and MCC-Specific Helper T Cells </line><line>(A) DiD-labeled OT-1 OVA-specific cells (red) were diluted 1:100 (top panels) or 1:1,000 (bottom panels) in DiO-labeled, monocyte-depleted </line><line>C57BL/6 mouse lymph node cells (green). DiD-labeled OT-1 cells of 2.7 3 10<sup>4</sup> (top panels) and 4.41 3 10<sup>3</sup> (bottom panels) were mixed, </line><line>respectively, with 2.7 310<sup>6</sup> and 4.41310<sup>6</sup> of DiO-labeled CD11b-depleted lymph node cells. The different dilutions were applied to identical but </line><line>separate arrays printed with the OVA/K<sup>b</sup> tetramer, the LCMV/K<sup>d</sup> control tetramer, and three different antibody spots (mouse anti-CD8, mouse </line><line>anti-CD4, and mouse anti-CD28). Following 10-min incubation at 378C, the cells were washed in RPMI and the slide was scanned. Shown are the </line><line>OT-1 (red) and lymph node (green) cells that were captured by the OVA tetramer (left), LCMV tetramer (second left), and the antibody spots. </line><line>(B) Class II MHC-mediated detection and sorting of helper T cells. DiD-labeled 5c.c7 lymphocytes (3.5 310<sup>4</sup>) (red) were diluted 100-fold in 3.6 3 <sub>1</sub><sub>0</sub><sub>6</sub> <sub>B</sub><sub>1</sub><sub>0</sub><sub>A</sub> <sub>D</sub><sub>i</sub><sub>O</sub> <sub>s</sub><sub>p</sub><sub>l</sub><sub>e</sub><sub>n</sub><sub>o</sub><sub>c</sub><sub>y</sub><sub>t</sub><sub>e</sub><sub>s</sub> <sub>(</sub><sub>g</sub><sub>r</sub><sub>e</sub><sub>e</sub><sub>n</sub><sub>)</sub><sub>.</sub> <sub>T</sub><sub>h</sub><sub>e</sub> <sub>m</sub><sub>i</sub><sub>x</sub><sub>e</sub><sub>d</sub> <sub>s</sub><sub>u</sub><sub>s</sub><sub>p</sub><sub>e</sub><sub>n</sub><sub>s</sub><sub>i</sub><sub>o</sub><sub>n</sub> <sub>w</sub><sub>a</sub><sub>s</sub> <sub>i</sub><sub>n</sub><sub>c</sub><sub>u</sub><sub>b</sub><sub>a</sub><sub>t</sub><sub>e</sub><sub>d</sub> <sub>a</sub><sub>t</sub> <sub>3</sub><sub>7</sub><sub>8</sub><sub>C</sub> <sub>f</sub><sub>o</sub><sub>r</sub> <sub>1</sub><sub>0</sub> <sub>m</sub><sub>i</sub><sub>n</sub> <sub>p</sub><sub>r</sub><sub>i</sub><sub>o</sub><sub>r</sub> <sub>t</sub><sub>o</sub> <sub>w</sub><sub>a</sub><sub>s</sub><sub>h</sub> <sub>w</sub><sub>i</sub><sub>t</sub><sub>h</sub> <sub>R</sub><sub>P</sub><sub>M</sub><sub>I</sub><sub>.</sub> <sub>S</sub><sub>h</sub><sub>o</sub><sub>w</sub><sub>n</sub> <sub>a</sub><sub>r</sub><sub>e</sub> <sub>t</sub><sub>h</sub><sub>e</sub> <sub>5</sub><sub>c</sub><sub>.</sub><sub>c</sub><sub>7</sub> <sub>s</sub><sub>e</sub><sub>l</sub><sub>l</sub><sub>s</sub> </line><line>(red) and splenocytes (green) captured by the MCC (left) and anti-CD28 (right) spots. </line><line>DOI: 10.1371/journal/pbio.0000065.g003 </line><line>PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 432 </line><line>Cellular Peptide–MHC Microarrays </line><line>be generated by the immune system. The T cell population in </line><line>each individual is diverse and dynamic. Even after exposure </line><line>to a potent T cell antigen, an individual TCR clone seldom </line><line>accounts for more than 5% of the total population of T cells </line><line>in a normal human or mouse. Moreover, the specificities and </line><line>phenotypes of the individual’s T cell repertoire may provide a </line><line>rich picture of the immunological history, the physiological </line><line>status, and perhaps the disease susceptibilities of that </line><line>individual. A broad picture of the dynamic responses of the </line><line>T cell repertoire to an immunological challenge should </line><line>illuminate our understanding of the immune response and </line><line>may point to individual-specific response patterns that can </line><line>help guide design of immunological therapies. </line><line>The development of peptide–MHC tetramers (Altman et al. </line><line>1996) and variations (Greten et al. 1998) as staining reagents </line><line>has greatly aided the analysis of antigen-specific populations </line><line>of CD4 and CD8 T cells. Unfortunately, the number of </line><line>specificities that can be analyzed is severely limited by the </line><line>fluorescence spectra available for conjugation to individual </line><line>peptide–MHC complexes. </line><line>Furthermore, the complex compensation required for </line><line>multiple fluorophores and numerous controls required for </line><line>adequate tetramer staining, such as a control tetramer, </line><line>propidium iodide for dead cell staining, anti-CD8, anti- </line><line>CD11, anti-CD19, and anti-CD56, further restrict the ability </line><line>to analyze multiple specificities simultaneously. Hence, </line><line>analyzing more than a few specificities is difficult and is </line><line>impractical for a typical clinical sample. By using specified, </line><line>predetermined spatial coordinates rather than fluorescent </line><line>tags, microarray technology has revolutionized the analysis of </line><line>gene and protein expression, allowing the simultaneous </line><line>analysis of hundreds to thousands of different variations in </line><line>gene and protein expression. This approach has been </line><line>recently used to analyze intact cells (Belov et al. 2001; Brown </line><line>et al. 2003), allowing the simultaneous characterization of </line><line>hundreds of cell surface molecules, by applying a homoge- </line><line>nous population of cells to an array of mAbs. We have </line><line>extended the experimental logic of that approach to the </line><line>characterization and isolation of antigen-specific populations </line><line>of T cells from a heterogeneous cell mixture. Furthermore, </line><line>cospotting peptide–MHCs with other effector molecules and/ </line><line>or co-culturing the T cells with other effector cells may allow </line><line>for high throughput examination of MHC presentation in the </line><line>context of other molecular signals and might open exciting </line><line>avenues for antigen-specific intercellular interaction assays. </line><line>Together, these methods should provide an efficient ap- </line><line>proach to epitope discovery and broad, systematic character- </line><line>ization of TCR specificity and the relations between epitope </line><line>recognition and T cell activation, reactivity, anergy, and cell </line><line>death. </line><line>Figure 4. Detection of a Weak Immune </line><line>Response to Vaccination </line><line>CTLs from OVA-vaccinated and mock- </line><line>vaccinated mice were analyzed in paral- </line><line>lel using an MHC array and flow cytom- </line><line>etry analysis. Mice received base-of-tail </line><line>injections of OVA/Freund’s adjuvant </line><line>emulsions or PBS (mock)/Freund’s adju- </line><line>vant on day 0 and day 7. Draining lymph </line><line>nodes were harvested on day 11, and </line><line>dissociated into a single-cell suspension. </line><line>(A) CTLs were enriched on an anti-CD8- </line><line>bead column. Cells (2 3 10<sup>6</sup> and 3.2 3 <sub>1</sub><sub>0</sub><sub>6</sub><sub>)</sub> <sub>f</sub><sub>r</sub><sub>o</sub><sub>m</sub> <sub>t</sub><sub>h</sub><sub>e</sub> <sub>O</sub><sub>V</sub><sub>A</sub><sub>-</sub> <sub>a</sub><sub>n</sub><sub>d</sub> <sub>m</sub><sub>o</sub><sub>c</sub><sub>k</sub><sub>-</sub><sub>v</sub><sub>a</sub><sub>c</sub><sub>c</sub><sub>i</sub><sub>-</sub> </line><line>nated mice, respectively, were incubated </line><line>on identical but separate arrays printed </line><line>with OVA/K<sup>b</sup> tetramer, LCMV/K<sup>d</sup> (con- </line><line>trol) tetramer, and various antibodies. </line><line>The three panels show the relevant array </line><line>results. A rare population of cells from </line><line>the OVA-vaccinated mouse was captured </line><line>on the OVA/K<sup>b</sup> (left), but not on the <sub>L</sub><sub>C</sub><sub>M</sub><sub>V</sub><sub>/</sub><sub>K</sub><sub>d</sub> <sub>(</sub><sub>r</sub><sub>i</sub><sub>g</sub><sub>h</sub><sub>t</sub><sub>)</sub><sub>,</sub> <sub>t</sub><sub>e</sub><sub>t</sub><sub>r</sub><sub>a</sub><sub>m</sub><sub>e</sub><sub>r</sub> <sub>s</sub><sub>p</sub><sub>o</sub><sub>t</sub><sub>.</sub> <sub>T</sub><sub>h</sub><sub>e</sub> <sub>c</sub><sub>e</sub><sub>l</sub><sub>l</sub><sub>s</sub> </line><line>captured on the OVA/K<sup>b</sup> tetramer spot </line><line>were CD8þ (as determined by counter- </line><line>staining using an anti-CD8–FITC mAb </line><line>on the array). An arrowhead points to </line><line>some of the cells that were bound to that </line><line>spot. The cells from the mock-vaccinated </line><line>mouse did not bind the OVA tetramer </line><line>(middle spot) or the LCMV/K<sup>d</sup> tetramer </line><line>(data not shown). Spot regions are </line><line>marked with a blue color by overlaying </line><line>the tetramer’s PE fluorescent signal onto </line><line>the DIC image. </line><line>(B) FACS analysis of the cells from the </line><line>OVA-vaccinated (left panel) and mock- </line><line>vaccinated mice (right). Of the total </line><line>CD8þ cells from the vaccinated mouse, <sub>0</sub><sub>.</sub><sub>2</sub><sub>7</sub><sub>%</sub> <sub>c</sub><sub>o</sub><sub>-</sub><sub>s</sub><sub>t</sub><sub>a</sub><sub>i</sub><sub>n</sub> <sub>w</sub><sub>i</sub><sub>t</sub><sub>h</sub> <sub>O</sub><sub>V</sub><sub>A</sub><sub>/</sub><sub>K</sub><sub>b</sub><sub>,</sub> <sub>c</sub><sub>o</sub><sub>m</sub><sub>p</sub><sub>a</sub><sub>r</sub><sub>e</sub><sub>d</sub> </line><line>with 0.01% in the mock-vaccinated </line><line>mouse. </line><line>DOI: 10.1371/journal/pbio.0000065.g004 </line><line>PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 433 </line><line>Cellular Peptide–MHC Microarrays </line><line>The excellent performance of peptide–MHC complexes as </line><line>binding probes in our cellular microarray format is somewhat </line><line>surprising because the typical TCR affinity is about 10<sup>3</sup>- to </line><line>10<sup>4</sup>-fold lower than that of a typical mAb and its antigen </line><line>(Davis et al. 1998). Still, sufficient numbers of peptide–MHC </line><line>complexes bound to a given cell can compensate for relatively </line><line>low affinity of a single peptide–MHC–TCR interaction. In </line><line>fact, a simple order of magnitude calculation shows that for a </line><line>typical peptide–MHC concentration, as few as approximately </line><line>200 peptide–MHC–TCR interactions are sufficient to capture </line><line>and stably hold a cell against typical flow forces experienced </line><line>during the washing of unbound cells (an example of this </line><line>calculation is provided in the Supporting Information </line><line>section). </line><line>The combination of large spots on an inert substrate allows </line><line>the reliable detection of as few as three to five bound cells per </line><line>spot. For cells with a diameter of 10 lm on a 400 lm spot, this </line><line>corresponds to a dynamic range of about 300-fold, which can </line><line>be further increased using larger spot sizes (i.e., dispensing </line><line>more drops on each spot) or using multiple spots of the same </line><line>size. More importantly, since rare populations of cells can be </line><line>detected only when a sufficient number of them encounter </line><line>the appropriate probe region, the total probe area (i.e., </line><line>surface area of one spot multiplied by the number of </line><line>identical spots) has a major effect on the sensitivity. We have </line><line>shown that the limit of detection with a single 400 lm spot of </line><line>a weak model antigen is about 0.1% (i.e., one positive out of </line><line>1,000 cells). Increasing the number of identical spots results </line><line>in an improvement in sensitivity, the extent of which is under </line><line>investigation. Further improvement might be achieved by </line><line>increased exposure of cells to each MHC-printed region (e.g., </line><line>by sample agitation, reloading, or directed flow). Another </line><line>route towards a significant improvement in both sensitivity </line><line>and signal-to-noise ratio is cell enrichment prior to MHC </line><line>array analysis. For example, preselection of CD8þ or CD4þ </line><line>from peripheral blood mononuclear cells (e.g., by bead </line><line>selection or FACS sorting) results in approximately a 10-fold </line><line>enrichment of specific target cells and eliminates the </line><line>nonspecific binding of a subpopulation of CD11bþ cells to </line><line>MHC spots. Further enrichment via negative and/or positive </line><line>selection using common markers would almost certainly </line><line>extend the lower limit of partial abundance required for </line><line>detection. </line><line>The number of cells captured on the array depends on the </line><line>abundance of cells expressing the appropriate TCR, its </line><line>expression level, and affinity to the peptide–MHC complex, </line><line>the concentration, functionality, and accessibility of that </line><line>complex, and several other factors, including the local cell </line><line>Figure 5. Activation of OT-1 Lymphocytes </line><line>Following an Exposure to Preprinted Spots </line><line>on an MHC Array </line><line>OT-1 lymphocytes were preloaded with </line><line>Fura-2 dye for 20 min at room temper- </line><line>ature prior to exposure to the cellular </line><line>microarray (time 0). The cells were </line><line>incubated at 378C, 5% CO<sub>2</sub>, and fluo- </line><line>rescence intensities at 340 nm and 380 </line><line>nm were measured every 30 s from each </line><line>of the spots on the array. Calcium flux </line><line>signal was triggered in the OVA-specific </line><line>cells as soon as they reached the OVA/K<sup>b</sup> </line><line>tetramer spots, the activating antibody </line><line>spots (anti-CD3 and anti-CD3/anti- </line><line>CD28), but not the irrelevant MCC/E<sup>k</sup> </line><line>tetramer or the nonactivating antibody </line><line>spots (e.g. anti-CD28). </line><line>(A) Calcium flux signal (yellow) overlaid </line><line>onto a 10x DIC image of OT-1 cells on a </line><line>combined FITC-labeled anti-CD3/anti- </line><line>CD28 spot. Fura-2 fluorescence intensity </line><line>ratios are represented in pseudo-color, </line><line>and the overlaid spot region (blue) is </line><line>determined from the FITC image. Note </line><line>that the spot pattern can be inferred </line><line>from the Fura-2 signal representing </line><line>activation, even without removing un- </line><line>bound cells. </line><line>(B) A time-lapsed series of images taken </line><line>of a representative OT-1 lymphocyte </line><line>specifically immobilized onto an OVA/ <sub>K</sub><sub>b</sub> <sub>s</sub><sub>p</sub><sub>o</sub><sub>t</sub><sub>.</sub> <sub>T</sub><sub>h</sub><sub>e</sub> <sub>c</sub><sub>e</sub><sub>l</sub><sub>l</sub> <sub>u</sub><sub>n</sub><sub>d</sub><sub>e</sub><sub>r</sub><sub>g</sub><sub>o</sub><sub>e</sub><sub>s</sub> <sub>a</sub> <sub>r</sub><sub>a</sub><sub>p</sub><sub>i</sub><sub>d</sub><sub>,</sub> </line><line>transient calcium flux as measured by </line><line>Fura-2 fluorescence. </line><line>(C) Averaged calcium flux traces (n </line><line>1⁄4 </line><line>3) </line><line>recorded from an </line><line>OVA/K<sup>b</sup> spot (purple </line><line>circles), anti-CD3/anti-CD28 spot (brown </line><line>triangles), anti-CD3 spot (green circles), </line><line>and nonactivating anti-CD28 spot (or- </line><line>ange triangles). Error bars represent </line><line>calculated standard error of mean. </line><line>DOI: 10.1371/journal/pbio.0000065.g005 </line><line>PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 434 </line><line>Cellular Peptide–MHC Microarrays </line><line>density, incubation, and washing conditions, local film, </line><line>integrity etc. Consequently, estimating the frequency of cells </line><line>expressing a given antigen specificity requires the develop- </line><line>ment of a standardized protocol. One possible approach is to </line><line>coexpose differentially labeled cell populations to the same </line><line>spots using a standard pool of T cells as a common internal </line><line>standard in each analysis, analogous to the reference RNA </line><line>commonly used for DNA microarray studies of gene </line><line>expression (Eisen and Brown 1999). The use of a common </line><line>internal standard can provide a way to eliminate local spot- </line><line>and slide-dependent factors and obtain a relative measure for </line><line>the number of cells that are above the threshold for </line><line>functional binding, allowing quantitative differential profil- </line><line>ing of cell surface markers based on the relative number of </line><line>bound cells. </line><line>The use of printed arrays of specific binding reagents for </line><line>characterizing populations of cells has similarities to FACS in </line><line>concept and applications. FACS has the advantage of allowing </line><line>analysis on a cell-by-cell basis, while the cellular microarray </line><line>approach allows a much larger number of molecules to be </line><line>analyzed in a population of cells. Currently, a single cellular </line><line>microarray can accommodate more than 1,000 peptide–MHC </line><line>probes (without decreasing the spot size), which allows </line><line>detection of 1,000 antigen-specific cell populations in a </line><line>single assay. Each cellular microarray-based assay is easy to </line><line>perform, utilizes fixed gating that eliminates the subjective </line><line>gating of FACS-based analysis, and allows many samples to be </line><line>analyzed side by side either on the same slide (for small </line><line>arrays) or on different slides. The high throughput should </line><line>make it practical to screen a sample population of cells (e.g., </line><line>from a patient) against a large panel of candidate peptide– </line><line>MHC complexes or to discover novel MHC-restricted </line><line>epitopes by screening libraries of random, mutated, and </line><line>chemically modified sequences. Although the fractional </line><line>abundance of specific T cells required for detection in our </line><line>experiments (0.1%) is not as low as can be detected in the best </line><line>FACS analyses (0.01%), it is already sufficient to identify an </line><line>immune response of clinical relevance and is likely to </line><line>improve with further optimization. </line><line>What are the prospects for efficient array-based detection </line><line>of immune responses and characterization of the TCR </line><line>recognition and activation landscape? The actual set of </line><line>TCR specificities and sensitivities, at any given time, depends </line><line>on the history of exposure to antigens, genotype, and the </line><line>physiological parameters. We have shown that a physiologi- </line><line>cally relevant response to an antigen challenge is detectable </line><line>as cell capture by the cognate peptide–MHC (see Figure 4). </line><line>Since an expanded population of activated T cells may cross- </line><line>react with epitopes having a considerable degree of sequence </line><line>homology (Reay et al. 1994; Wucherpfennig and Strominger </line><line>1995; Kersh and Allen 1996; Bach et al. 1998; Honeyman et al. </line><line>1998; Mason 1998; Zhao et al. 1998; Hiemstra et al. 1999; </line><line>Misko et al. 1999), a signature of binding to multiple peptides </line><line>is also possible, especially for structurally similar epitopes </line><line>(high surface concentration of the peptide–MHC may further </line><line>contribute to the ability to capture cross-reacting T cells). </line><line>Moreover, in numerous important pathologies associated </line><line>with both specific and nonspecific polyclonal activation of </line><line>the host immune system, the binding of activated clones to </line><line>many unrelated (and often self-protein-derived) peptides is </line><line>very plausible. For example, a single cancer patient can </line><line>develop immune responses to multiple tumor-associated </line><line>antigens (Rosenberg 2001). In one case, tumor-infiltrating </line><line>lymphocytes from a single patient recognized tyrosinase (a </line><line>differentiation antigen presented by human leucocyte anti- </line><line>gen [HLA] class I), b-catenin (a class I mutation), p15 (a class I </line><line>antigen involved in posttranscriptional control), gp100 (a </line><line>class I intronic sequence and class II normal sequence), </line><line>tyrosinase-related protein-1 (TRP-1, a class II differentiation </line><line>antigen), TRP-2 (a class II differentiation antigen), and Ki-67 </line><line>(a class II mutation). </line><line>The wide range of specificities against nonhomologous </line><line>antigens demonstrated in this and other reports strongly </line><line>supports the feasibility of cellular microarray-based charac- </line><line>terization of patient-specific immune response patterns. An </line><line>example for a nonspecific, clinically important response is a </line><line>superantigen-induced stimulation, which often leads to a </line><line>massive polyclonal lymphocyte activation that might account </line><line>for up to 30% of the host T cell repertoire (depending on the </line><line>number of V<sub>b</sub> families capable of interacting with the </line><line>superantigen) (Muller-Alouf et al. 2001). Still, while the </line><line>cellular microarray should be sensitive enough to identify </line><line>and examine binding patterns in activated samples, its ability </line><line>to characterize the naive repertoire might be limited. This </line><line>drawback may be mitigated by modifying the geometry of the </line><line>array and/or the sample introduction method so as to </line><line>increase the chances of rare cell populations encountering </line><line>each of the peptide–MHC complexes. </line><line>Taking advantage of the full potential of this approach </line><line>requires convenient means for synthesizing diverse arrays of </line><line>peptide–MHC complexes. Conventional MHC tetramer syn- </line><line>thesis is cumbersome and technically difficult, making the </line><line>effective implementation of large, functional peptide–MHC </line><line>libraries a practical challenge. However, usage of reloadable </line><line>MHC constructs such as DimerX (BD Biosciences) or the </line><line>MHC tetramer-based Epitope Discovery System (Beckman </line><line>Coulter) should allow for an efficient production of printable </line><line>MHC molecules loaded with diverse peptide epitopes of </line><line>interest. Indeed, preliminary experiments suggest that the </line><line>DimerX peptide-loadable reagent has a similar specificity and </line><line>sensitivity to that of peptide–MHC tetramers. </line><line>The experimental strategy introduced here provides a </line><line>powerful tool for simultaneous detection and study of </line><line>antigen-specific T cell populations. This technique can be </line><line>performed rapidly (10 min), requires little technical exper- </line><line>tise, and allows screening of a single clinical sample (with </line><line>CD4þ and/or CD8þ T cells) against a library of specific or </line><line>random peptide–MHCs. Although the data presented here </line><line>were generated using cells derived from mice, preliminary </line><line>results indicate that this approach works equally well with </line><line>human samples. Numerous clinically significant MHC-re- </line><line>stricted epitopes have already been defined. These can be </line><line>easily printed on a single microarray to provide a rapid test </line><line>for the cognate T cell responses and to study the involvement </line><line>of multiple epitopes during the course of a disease or </line><line>following vaccination. Co-immobilization with effector mol- </line><line>ecules and cells may assist in identifying key factors that take </line><line>part in the regulation of T cell effector function. Thus, the </line><line>development of peptide–MHC cellular microarrays should </line><line>provide valuable insights into dynamic and individual </line><line>variations in the global repertoire of T cell specificities and </line><line>the mechanisms that control them. </line><line>PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 435 </line><line>Cellular Peptide–MHC Microarrays </line><line>Materials and Methods </line><line>Peptides and cell lines. MCC 88–103 (ANERADLIAYLKQATK), </line><line>OVA 258–265 (SIINFEKL), HIV gag 77–85 (SLYNTVATL), and LCMV </line><line>gp1 33–41 (KAVYNFATC) peptides have been produced at the </line><line>Protein and Nucleic Acid Facility at Stanford University (Stanford, </line><line>California, United States). </line><line>OT-1 TCR transgenic mice (Hogquist et al. 1994) bred into a wild- </line><line>type C57BL/6 background (Fazekas de St. Groth et al. 1993), </line><line>expressing homozygous for MHC class I-restricted OVA-specific </line><line>TCR, were a generous gift from Dr. Stephen Schoenberger (San </line><line>Diego, California, United States). 5c.c7 areTCR transgenic mice </line><line>expressing homozygous for MHC class II MCC-specific TCR. Animals </line><line>were housed in a pathogen-free condition. </line><line>Peptide–MHC class I tetramer preparation and staining. This </line><line>technique was developed in the Davis lab (Altman et al. 1996) and has </line><line>been widely used. In brief, a 15 amino acid linker/BirA substrate </line><line>peptide (BSP) for BirA-dependent biotinylation has been genetically </line><line>engineered onto the COOH terminus of the mouse </line><line>H-2K<sup>b</sup> </line><line>or </line><line>I-E<sup>k</sup> </line><line>gene. The MHC class I/BirA substrate peptide fusion protein was <sub>e</sub><sub>x</sub><sub>p</sub><sub>r</sub><sub>e</sub><sub>s</sub><sub>s</sub><sub>e</sub><sub>d</sub> <sub>i</sub><sub>n</sub> <sub>E</sub><sub>s</sub><sub>c</sub><sub>h</sub><sub>e</sub><sub>r</sub><sub>i</sub><sub>c</sub><sub>h</sub><sub>i</sub><sub>a</sub> <sub>c</sub><sub>o</sub><sub>l</sub><sub>i</sub> <sub>w</sub><sub>i</sub><sub>t</sub><sub>h</sub> <sub>b</sub><sub>2</sub><sub>-</sub><sub>m</sub><sub>i</sub><sub>c</sub><sub>r</sub><sub>o</sub><sub>g</sub><sub>l</sub><sub>o</sub><sub>b</sub><sub>u</sub><sub>l</sub><sub>i</sub><sub>n</sub> <sub>a</sub><sub>n</sub><sub>d</sub> <sub>f</sub><sub>o</sub><sub>l</sub><sub>d</sub><sub>e</sub><sub>d</sub> <sub>i</sub><sub>n</sub> <sub>v</sub><sub>i</sub><sub>t</sub><sub>r</sub><sub>o</sub> </line><line>with specific peptide ligands. The properly folded peptide–MHC class </line><line>I–b<sub>2</sub>-microglobulin complex was then extensively purified and </line><line>biotinylated on a lysine residue within the BSP using the BirA </line><line>enzyme (Avidity, Denver, Colorado, United States). Tetramers were <sub>p</sub><sub>r</sub><sub>o</sub><sub>d</sub><sub>u</sub><sub>c</sub><sub>e</sub><sub>d</sub> <sub>b</sub><sub>y</sub> <sub>a</sub><sub>d</sub><sub>d</sub><sub>i</sub><sub>n</sub><sub>g</sub> <sub>t</sub><sub>o</sub> <sub>b</sub><sub>i</sub><sub>o</sub><sub>t</sub><sub>i</sub><sub>n</sub><sub>y</sub><sub>l</sub><sub>a</sub><sub>t</sub><sub>e</sub><sub>d</sub> <sub>p</sub><sub>e</sub><sub>p</sub><sub>t</sub><sub>i</sub><sub>d</sub><sub>e</sub><sub>–</sub><sub>M</sub><sub>H</sub><sub>C</sub> <sub>c</sub><sub>o</sub><sub>m</sub><sub>p</sub><sub>l</sub><sub>e</sub><sub>x</sub><sub>e</sub><sub>s</sub> <sub>P</sub><sub>E</sub><sub>–</sub><sub>S</sub><sub>A</sub> </line><line>(Prozyme, San Leandro, California, United States) at a molar ratio of </line><line>4:1. Specificity is demonstrated by lack of staining in irrelevant CTLs. </line><line>Tetramers were individually titrated and used at the optimum </line><line>concentration based on signal-to-noise ratio, usually 10 lg/ml. LCMV/ <sub>K</sub><sub>d</sub> </line><line>was purchased from Beckman Coulter (Allendale, New Jersey, </line><line>United States). Cells (1 310<sup>6</sup>) </line><line>were stained with the specific tetramer </line><line>of interest for 30 min at 48C. Antibodies were then added at the </line><line>recommended concentrations and incubated for 30 min at 48C. </line><line>Preparation of MHC and antibody arrays. The following MHC </line><line>tetramers and antibodies were prepared in a v-shaped 384-well plate </line><line>(Genetix Pharmaceuticals, Cambridge, Massachusetts, United States) </line><line>with approximately 12 ll per well: (i) a 2-fold dilution series of OVA/ <sub>H</sub><sub>-</sub><sub>2</sub><sub>K</sub><sub>b</sub> <sub>t</sub><sub>e</sub><sub>t</sub><sub>r</sub><sub>a</sub><sub>m</sub><sub>e</sub><sub>r</sub> <sub>(</sub><sub>1</sub> <sub>t</sub><sub>o</sub> <sub>1</sub><sub>:</sub><sub>1</sub><sub>6</sub><sub>3</sub><sub>,</sub> <sub>w</sub><sub>i</sub><sub>t</sub><sub>h</sub> <sub>1</sub><sub>3</sub><sub>c</sub><sub>o</sub><sub>n</sub><sub>c</sub><sub>e</sub><sub>n</sub><sub>t</sub><sub>r</sub><sub>a</sub><sub>t</sub><sub>i</sub><sub>o</sub><sub>n</sub> <sub>b</sub><sub>e</sub><sub>i</sub><sub>n</sub><sub>g</sub> <sub>0</sub><sub>.</sub><sub>1</sub><sub>7</sub> <sub>m</sub><sub>g</sub><sub>/</sub><sub>m</sub><sub>l</sub><sub>)</sub><sub>,</sub> </line><line>(ii) gp100/HLA-A2 tetramer (at 0.52 mg/ml), (iii) MCC/I-E<sup>k</sup> tetramer </line><line>(0.42 mg/ml), (iv) LCMV/H-2K<sup>d</sup> tetramer (Beckman Coulter) at 0.33 </line><line>mg/ml, (v) mouse anti-CD3 mAb (clone 17A2; BD Pharmingen, San </line><line>Diego, California, United States) at 0.5 mg/ml, (vi) mouse anti-CD28 </line><line>mAb (clone 37.51; BD Pharmingen) at 0.5 mg/ml, and (vii) a 1:1 </line><line>mixture of mouse anti-CD3 and mouse anti-CD28 (each at a final </line><line>concentration of 0.25 mg/ml). Each of the tetramer and DimerX </line><line>solutions were supplemented with 2% glycerol. All samples were <sub>a</sub><sub>r</sub><sub>r</sub><sub>a</sub><sub>y</sub><sub>e</sub><sub>d</sub> <sub>i</sub><sub>n</sub> <sub>t</sub><sub>r</sub><sub>i</sub><sub>p</sub><sub>l</sub><sub>i</sub><sub>c</sub><sub>a</sub><sub>t</sub><sub>e</sub><sub>s</sub> <sub>o</sub><sub>n</sub><sub>t</sub><sub>o</sub> <sub>t</sub><sub>h</sub><sub>r</sub><sub>e</sub><sub>e</sub><sub>-</sub><sub>d</sub><sub>i</sub><sub>m</sub><sub>e</sub><sub>n</sub><sub>s</sub><sub>i</sub><sub>o</sub><sub>n</sub><sub>a</sub><sub>l</sub> <sub>s</sub><sub>u</sub><sub>b</sub><sub>s</sub><sub>t</sub><sub>r</sub><sub>a</sub><sub>t</sub><sub>e</sub><sub>s</sub> <sub>c</sub><sub>o</sub><sub>m</sub><sub>p</sub><sub>r</sub><sub>i</sub><sub>s</sub><sub>e</sub><sub>d</sub> <sub>o</sub><sub>f</sub> </line><line>microscope slides coated with a polyacrylamide gel (Perkin Elmer, </line><line>Boston, Massachusetts, United States). Slides were processed for </line><line>printing according to the manufacturer’s instructions, and the </line><line>samples were then dispensed with a noncontact piezo-electric arrayer <sub>(</sub><sub>P</sub><sub>e</sub><sub>r</sub><sub>k</sub><sub>i</sub><sub>n</sub> <sub>E</sub><sub>l</sub><sub>m</sub><sub>e</sub><sub>r</sub><sub>)</sub><sub>.</sub> <sub>A</sub><sub>b</sub><sub>o</sub><sub>u</sub><sub>t</sub> <sub>4</sub><sub>.</sub><sub>5</sub> <sub>n</sub><sub>l</sub> <sub>o</sub><sub>f</sub> <sub>s</sub><sub>a</sub><sub>m</sub><sub>p</sub><sub>l</sub><sub>e</sub> <sub>(</sub><sub>1</sub><sub>0</sub> <sub>d</sub><sub>r</sub><sub>o</sub><sub>p</sub><sub>s</sub> <sub>o</sub><sub>f</sub> <sub>a</sub><sub>p</sub><sub>p</sub><sub>r</sub><sub>o</sub><sub>x</sub><sub>i</sub><sub>m</sub><sub>a</sub><sub>t</sub><sub>e</sub><sub>l</sub><sub>y</sub> </line><line>0.45 nl) were dispensed on each spot (approximately 400 lm in </line><line>diameter). To allow for more than one independent assay on each </line><line>slide, each of the samples (or, in some cases, part of the samples) was <sub>d</sub><sub>i</sub><sub>s</sub><sub>p</sub><sub>e</sub><sub>n</sub><sub>s</sub><sub>e</sub><sub>d</sub> <sub>i</sub><sub>n</sub> <sub>t</sub><sub>w</sub><sub>o</sub> <sub>g</sub><sub>r</sub><sub>o</sub><sub>u</sub><sub>p</sub><sub>s</sub> <sub>(</sub><sub>o</sub><sub>r</sub> <sub>b</sub><sub>l</sub><sub>o</sub><sub>c</sub><sub>k</sub><sub>s</sub><sub>)</sub> <sub>w</sub><sub>i</sub><sub>t</sub><sub>h</sub> <sub>a</sub><sub>n</sub> <sub>i</sub><sub>n</sub><sub>t</sub><sub>e</sub><sub>r</sub><sub>g</sub><sub>r</sub><sub>o</sub><sub>u</sub><sub>p</sub> <sub>d</sub><sub>i</sub><sub>s</sub><sub>t</sub><sub>a</sub><sub>n</sub><sub>c</sub><sub>e</sub> <sub>o</sub><sub>f</sub> <sub>5</sub> </line><line>mm. Following the print run, the arrayed proteins were immobilized </line><line>within the gel substrate by incubating the slides for 24 h at 48C in a </line><line>humid chamber. Following the immobilization, the arrays were <sub>p</sub><sub>l</sub><sub>a</sub><sub>c</sub><sub>e</sub><sub>d</sub> <sub>i</sub><sub>n</sub> <sub>a</sub> <sub>d</sub><sub>r</sub><sub>y</sub> <sub>s</sub><sub>l</sub><sub>i</sub><sub>d</sub><sub>e</sub> <sub>b</sub><sub>o</sub><sub>x</sub><sub>,</sub> <sub>s</sub><sub>e</sub><sub>a</sub><sub>l</sub><sub>e</sub><sub>d</sub> <sub>w</sub><sub>i</sub><sub>t</sub><sub>h</sub> <sub>t</sub><sub>a</sub><sub>p</sub><sub>e</sub><sub>,</sub> <sub>a</sub><sub>n</sub><sub>d</sub> <sub>s</sub><sub>t</sub><sub>o</sub><sub>r</sub><sub>e</sub><sub>d</sub> <sub>a</sub><sub>t</sub> <sub>4</sub><sub>8</sub><sub>C</sub> <sub>u</sub><sub>n</sub><sub>t</sub><sub>i</sub><sub>l</sub> </line><line>used. Stored slides were used for 5 mo without an observed reduction </line><line>in activity or diffusion of the spotted constructs (lack of diffusion was </line><line>determined by examining the diameter of the PE-labeled MHC </line><line>tetramer spots as viewed by fluorescence microscopy). </line><line>Array panning. OT-1 and 5c.c7 transgenic mice were sacrificed on <sub>d</sub><sub>a</sub><sub>y</sub> <sub>0</sub> <sub>b</sub><sub>y</sub> <sub>c</sub><sub>e</sub><sub>r</sub><sub>v</sub><sub>i</sub><sub>c</sub><sub>a</sub><sub>l</sub> <sub>d</sub><sub>i</sub><sub>s</sub><sub>l</sub><sub>o</sub><sub>c</sub><sub>a</sub><sub>t</sub><sub>i</sub><sub>o</sub><sub>n</sub><sub>.</sub> <sub>A</sub><sub>x</sub><sub>i</sub><sub>l</sub><sub>l</sub><sub>a</sub><sub>r</sub><sub>y</sub> <sub>a</sub><sub>n</sub><sub>d</sub> <sub>i</sub><sub>n</sub><sub>g</sub><sub>u</sub><sub>i</sub><sub>n</sub><sub>a</sub><sub>l</sub> <sub>l</sub><sub>y</sub><sub>m</sub><sub>p</sub><sub>h</sub> <sub>n</sub><sub>o</sub><sub>d</sub><sub>e</sub><sub>s</sub> <sub>w</sub><sub>e</sub><sub>r</sub><sub>e</sub> </line><line>harvested and a single-cell suspension obtained by straining through </line><line>a 70-lm cell strainer (BD Falcon, San Diego, California, United </line><line>States) in RPMI fortified with 10% fetal calf serum (FCS), penicillin, </line><line>streptomycin, glutamine, b-mercaptoethanol, and nonessential amino </line><line>acids. OVA or MCC peptide (1 lM) was then added and the cells were </line><line>incubated at 378C. On day 1, murine IL-2 (Sigma, St. Louis, Missouri, </line><line>United States) was added to the lymphocytes to a final concentration </line><line>of 30 U/ml. On days 7–10, lymphocytes were suspended in RPMI </line><line>(deficient in phenol red) with 5% FCS at a concentration of 10<sup>4</sup>–10<sup>8</sup> </line><line>cells/ml prior to incubation on the peptide–MHC tetramer array. </line><line>B10A or C57BL/6 mice were sacrificed, and single-cell splenocyte </line><line>suspensions was subjected to a Ficol gradient and CD11bNO_UNICODE depletion </line><line>(Miltenyi Biotec, Bergisch Gladbach, Germany) prior to being used as </line><line>syngeneic controls. Cells were labeled with fluorescent lipophilic </line><line>tracers DiO, DiD, and DiI (Molecular Probes, Eugene, Oregon, United </line><line>States) according to the manufacturer’s instructions. Labeled or </line><line>unlabeled cells were directly added to the peptide–MHC array by </line><line>gentle layering in volumes of 20–50 ll. The array was incubated either </line><line>at 378C or 208C for 10–30 min. Following incubation, the array was </line><line>washed twice with RPMI to remove unbound cells. (For more detailed </line><line>information, see Protocol S1.) </line><line>Detection of a weak postvaccine immune response. MHC arrays </line><line>were used to monitor CD8-specific immune responses to OVA </line><line>vaccination in wild-type C57BL/6 mice. Mice received base-of-tail </line><line>injections of 1:1 OVA (100 lg in 100 ll of phosphate-buffered saline </line><line>[PBS]; Sigma)/Freund’s adjuvant (Sigma) emulsions or PBS/Freund’s </line><line>adjuvant (mock vaccination) on day 0 and day 7. Mice were sacrificed </line><line>on day 11 and underwent anti-CD8þ selection (Miltenyi Biotec) from </line><line>single-cell suspensions derived from mouse lymph nodes. CD8þ </line><line>lymphocytes from both OVA- and mock-vaccinated mice were <sub>a</sub><sub>p</sub><sub>p</sub><sub>l</sub><sub>i</sub><sub>e</sub><sub>d</sub> <sub>t</sub><sub>o</sub> <sub>s</sub><sub>e</sub><sub>p</sub><sub>a</sub><sub>r</sub><sub>a</sub><sub>t</sub><sub>e</sub> <sub>M</sub><sub>H</sub><sub>C</sub> <sub>a</sub><sub>r</sub><sub>r</sub><sub>a</sub><sub>y</sub><sub>s</sub><sub>.</sub> <sub>F</sub><sub>A</sub><sub>C</sub><sub>S</sub> <sub>a</sub><sub>n</sub><sub>a</sub><sub>l</sub><sub>y</sub><sub>s</sub><sub>i</sub><sub>s</sub> <sub>o</sub><sub>f</sub> <sub>t</sub><sub>h</sub><sub>e</sub> <sub>s</sub><sub>a</sub><sub>m</sub><sub>e</sub> <sub>p</sub><sub>o</sub><sub>p</sub><sub>u</sub><sub>l</sub><sub>a</sub><sub>t</sub><sub>i</sub><sub>o</sub><sub>n</sub> <sub>o</sub><sub>f</sub> <sub>c</sub><sub>e</sub><sub>l</sub><sub>l</sub><sub>s</sub> <sub>w</sub><sub>a</sub><sub>s</sub> <sub>p</sub><sub>e</sub><sub>r</sub><sub>f</sub><sub>o</sub><sub>r</sub><sub>m</sub><sub>e</sub><sub>d</sub> <sub>a</sub><sub>s</sub> <sub>d</sub><sub>e</sub><sub>t</sub><sub>a</sub><sub>i</sub><sub>l</sub><sub>e</sub><sub>d</sub> <sub>a</sub><sub>b</sub><sub>o</sub><sub>v</sub><sub>e</sub><sub>,</sub> <sub>w</sub><sub>i</sub><sub>t</sub><sub>h</sub> <sub>a</sub><sub>n</sub><sub>t</sub><sub>i</sub><sub>-</sub> </line><line>CD8–FITC mAb, OVA/K<sup>b</sup> SA–PE tetramer, and an HIV gag 77–85/ </line><line>HLA-A*0201 SA–PerCP dump tetramer. FACS analysis was per- </line><line>formed on a Becton Dickenson LSR at the Stanford University FACS </line><line>Facility (Stanford, California, United States). </line><line>Intracellular calcium measurements. To determine whether the </line><line>MHC array could be used to probe intact lymphocyte activation </line><line>pathways, OT-1 lymphocytes were loaded with 5 lg/ml calcium- </line><line>sensitive dye Fura-2 (Molecular Probes) for 20 min at room </line><line>temperature. The lymphocytes were then exposed to an MHC array <sub>c</sub><sub>o</sub><sub>n</sub><sub>t</sub><sub>a</sub><sub>i</sub><sub>n</sub><sub>i</sub><sub>n</sub><sub>g</sub> <sub>O</sub><sub>V</sub><sub>A</sub><sub>/</sub><sub>K</sub><sub>b</sub><sub>,</sub> <sub>L</sub><sub>C</sub><sub>M</sub><sub>V</sub><sub>/</sub><sub>K</sub><sub>d</sub><sub>,</sub> <sub>M</sub><sub>C</sub><sub>C</sub><sub>/</sub><sub>E</sub><sub>k</sub><sub>,</sub> <sub>a</sub><sub>n</sub><sub>t</sub><sub>i</sub><sub>-</sub><sub>C</sub><sub>D</sub><sub>3</sub><sub>,</sub> <sub>a</sub><sub>n</sub><sub>t</sub><sub>i</sub><sub>-</sub><sub>C</sub><sub>D</sub><sub>2</sub><sub>8</sub><sub>,</sub> <sub>a</sub><sub>n</sub><sub>d</sub> </line><line>anti-CD3/anti-CD28 spots. Intracellular calcium levels were moni- </line><line>tored every 30 s by measuring the ratio of the fluorescence intensity </line><line>at 340 nm and 380 nm using the fluorescence microscopy equipment </line><line>detailed below. </line><line>Array imaging. Imaging was performed using a Zeiss (Oberkochen, </line><line>Germany) Axiovert-100TV microscope and a Fluor 10x fitted with a <sub>h</sub><sub>i</sub><sub>g</sub><sub>h</sub><sub>-</sub><sub>s</sub><sub>p</sub><sub>e</sub><sub>e</sub><sub>d</sub> <sub>p</sub><sub>i</sub><sub>e</sub><sub>z</sub><sub>o</sub><sub>-</sub><sub>e</sub><sub>l</sub><sub>e</sub><sub>c</sub><sub>t</sub><sub>r</sub><sub>i</sub><sub>c</sub> <sub>z</sub><sub>-</sub><sub>m</sub><sub>o</sub><sub>t</sub><sub>o</sub><sub>r</sub> <sub>(</sub><sub>P</sub><sub>h</sub><sub>y</sub><sub>s</sub><sub>i</sub><sub>k</sub> <sub>I</sub><sub>n</sub><sub>s</sub><sub>t</sub><sub>r</sub><sub>u</sub><sub>m</sub><sub>e</sub><sub>n</sub><sub>t</sub><sub>s</sub><sub>,</sub> <sub>D</sub><sub>o</sub><sub>w</sub><sub>n</sub><sub>i</sub><sub>n</sub><sub>g</sub><sub>-</sub> </line><line>town, Pennsylvania, United States), Princeton Instruments liquid- </line><line>cooled CCD Interline camera (Roper Scientific, Trenton, New Jersey, </line><line>United States), and dual excitation and emission filter wheels (Sutter </line><line>Instruments, Novato, California, United States). A DIC image, a Cy3 </line><line>(for DiI or PE), a Cy5 (DiD) and/or a FITC (DiO) image, and/or 340 nm </line><line>and 380 nm images were collected every 30 s for up to 1 h. </line><line>Microscope control, acquisition of data, and image analysis were <sub>p</sub><sub>e</sub><sub>r</sub><sub>f</sub><sub>o</sub><sub>r</sub><sub>m</sub><sub>e</sub><sub>d</sub> <sub>u</sub><sub>s</sub><sub>i</sub><sub>n</sub><sub>g</sub> <sub>M</sub><sub>e</sub><sub>t</sub><sub>a</sub><sub>m</sub><sub>o</sub><sub>r</sub><sub>p</sub><sub>h</sub> <sub>(</sub><sub>U</sub><sub>n</sub><sub>i</sub><sub>v</sub><sub>e</sub><sub>r</sub><sub>s</sub><sub>a</sub><sub>l</sub> <sub>I</sub><sub>m</sub><sub>a</sub><sub>g</sub><sub>i</sub><sub>n</sub><sub>g</sub><sub>,</sub> <sub>D</sub><sub>o</sub><sub>w</sub><sub>n</sub><sub>i</sub><sub>n</sub><sub>g</sub><sub>t</sub><sub>o</sub><sub>w</sub><sub>n</sub><sub>,</sub> </line><line>Pennsylvania, United States). </line><line>Supporting Information </line><line>To evaluate the effect of tetramer dilution on cell capture, we <sub>p</sub><sub>r</sub><sub>i</sub><sub>n</sub><sub>t</sub><sub>e</sub><sub>d</sub> <sub>a</sub><sub>n</sub> </line><line>OVA/k<sup>b</sup> tetramer dilution series and probed it with OT-1 </line><line>cells (Figure S1A). The cells were suspended at 2.5 310<sup>6</sup> cell/ml (10<sup>5</sup> </line><line>cells in 40 ll), which was below the concentration required for </line><line>confluent coverage of the spot area. The cells were then incubated </line><line>with the array (30 min at room temperature) and imaged following </line><line>washout of unbound cells. In this specific example, the number of </line><line>cells captured increased linearly with the amount of tetramer </line><line>deposited (Figure S1B), with a binding threshold of approximately </line><line>0.05 ng/spot. The lack of plateau at high tetramer concentrations, </line><line>together with the denser cell coverage on the anti-CD3 spots, suggests </line><line>that a still further increase in tetramer concentration (without </line><line>changing the suspension density) would result in higher numbers of </line><line>bound cells. Indeed, a 4-fold increase in the amount of tetramer </line><line>deposited leads to a significant increase in binding efficiency, which </line><line>becomes comparable to binding via a mAb (data not shown). The lack </line><line>of cell binding between spots or to noncognate peptide–MHC spots </line><line>indicates that binding of as low as a few cells is attributable to </line><line>peptide–MHC–TCR recognition. Note, however, that the linear shape </line><line>of the binding curve (Figure S1B) should be considered as a special </line><line>case and not as a general rule. Likewise, the minimal concentration </line><line>for binding depends on the availability and functionality of the </line><line>immobilized peptide–MHC, the peptide–MHC–TCR affinity, the </line><line>type, density, and heterogeneity of the cells, the incubation temper- </line><line>ature and duration, and the stringency of washing. </line><line>In general, the binding curve should depend on the immobilization </line><line>kinetics, the heterogeneity in TCR expression level, and its affinity to </line><line>the peptide–MHC complex. For a sufficiently dense, homogeneous </line><line>cell suspension, we expect to find a sigmoidal binding curve with a <sub>s</sub><sub>h</sub><sub>a</sub><sub>r</sub><sub>p</sub> <sub>t</sub><sub>r</sub><sub>a</sub><sub>n</sub><sub>s</sub><sub>i</sub><sub>t</sub><sub>i</sub><sub>o</sub><sub>n</sub> <sub>f</sub><sub>r</sub><sub>o</sub><sub>m</sub> <sub>n</sub><sub>o</sub> <sub>b</sub><sub>i</sub><sub>n</sub><sub>d</sub><sub>i</sub><sub>n</sub><sub>g</sub> <sub>t</sub><sub>o</sub> <sub>a</sub> <sub>p</sub><sub>l</sub><sub>a</sub><sub>t</sub><sub>e</sub><sub>a</sub><sub>u</sub> <sub>a</sub><sub>t</sub> <sub>s</sub><sub>o</sub><sub>m</sub><sub>e</sub> <sub>c</sub><sub>r</sub><sub>i</sub><sub>t</sub><sub>i</sub><sub>c</sub><sub>a</sub><sub>l</sub> </line><line>tetramer concentration. Indeed, in some other peptide–MHC–TCR </line><line>PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 436 </line><line>Cellular Peptide–MHC Microarrays </line><line>systems (and higher suspension densities), the binding curve has a <sub>s</sub><sub>i</sub><sub>g</sub><sub>m</sub><sub>o</sub><sub>i</sub><sub>d</sub><sub>a</sub><sub>l</sub> <sub>s</sub><sub>h</sub><sub>a</sub><sub>p</sub><sub>e</sub> <sub>(</sub><sub>d</sub><sub>a</sub><sub>t</sub><sub>a</sub> <sub>n</sub><sub>o</sub><sub>t</sub> <sub>s</sub><sub>h</sub><sub>o</sub><sub>w</sub><sub>n</sub><sub>)</sub><sub>.</sub> <sub>H</sub><sub>e</sub><sub>t</sub><sub>e</sub><sub>r</sub><sub>o</sub><sub>g</sub><sub>e</sub><sub>n</sub><sub>e</sub><sub>i</sub><sub>t</sub><sub>y</sub> <sub>i</sub><sub>n</sub> <sub>T</sub><sub>C</sub><sub>R</sub> <sub>a</sub><sub>f</sub><sub>fi</sub><sub>n</sub><sub>i</sub><sub>t</sub><sub>y</sub> <sub>a</sub><sub>n</sub><sub>d</sub> </line><line>expression level should lead to a less steep increase in captured cell </line><line>number as a function of surface ligand density. Therefore, the linear </line><line>binding curve (Figure S1B) probably reflects a wide distribution of </line><line>TCR expression levels and/or affinities and should not be considered </line><line>as a pure statement on binding kinetics. Still, an exact linear curve is </line><line>somewhat surprising. </line><line>The excellent performance of peptide–MHC complexes as binding </line><line>probes in an array format was somewhat surprising because the </line><line>typical TCR affinity is about 10<sup>3</sup>- to 10<sup>4</sup>-fold lower than that of a <sub>t</sub><sub>y</sub><sub>p</sub><sub>i</sub><sub>c</sub><sub>a</sub><sub>l</sub> <sub>m</sub><sub>A</sub><sub>b</sub> <sub>a</sub><sub>n</sub><sub>d</sub> <sub>i</sub><sub>t</sub><sub>s</sub> <sub>a</sub><sub>n</sub><sub>t</sub><sub>i</sub><sub>g</sub><sub>e</sub><sub>n</sub> <sub>(</sub><sub>D</sub><sub>a</sub><sub>v</sub><sub>i</sub><sub>s</sub> <sub>e</sub><sub>t</sub> <sub>a</sub><sub>l</sub><sub>.</sub> <sub>1</sub><sub>9</sub><sub>9</sub><sub>8</sub><sub>)</sub><sub>.</sub> <sub>S</sub><sub>t</sub><sub>i</sub><sub>l</sub><sub>l</sub><sub>,</sub> <sub>s</sub><sub>u</sub><sub>f</sub><sub>fi</sub><sub>c</sub><sub>i</sub><sub>e</sub><sub>n</sub><sub>t</sub> </line><line>numbers of peptide–MHC complexes bound to a given cell can </line><line>compensate for relatively low affinity of a single peptide–MHC–TCR </line><line>bond. By incorporating kinetic parameters specific to the OT-1/OVA </line><line>tetramer interaction into a simplified adhesion model proposed by </line><line>Bell (1978), the actual number of OT-1/OVA/K<sup>b</sup> tetramer bonds can </line><line>be estimated as follows. Each spot typically contains approximately 2 <sub>3</sub><sub>1</sub><sub>0</sub><sub>1</sub><sub>0</sub> <sub>t</sub><sub>e</sub><sub>t</sub><sub>r</sub><sub>a</sub><sub>m</sub><sub>e</sub><sub>r</sub><sub>s</sub><sub>,</sub> <sub>c</sub><sub>o</sub><sub>r</sub><sub>r</sub><sub>e</sub><sub>s</sub><sub>p</sub><sub>o</sub><sub>n</sub><sub>d</sub><sub>i</sub><sub>n</sub><sub>g</sub> <sub>t</sub><sub>o</sub> <sub>a</sub> <sub>m</sub><sub>a</sub><sub>x</sub><sub>i</sub><sub>m</sub><sub>a</sub><sub>l</sub> <sub>s</sub><sub>u</sub><sub>r</sub><sub>f</sub><sub>a</sub><sub>c</sub><sub>e</sub> <sub>c</sub><sub>o</sub><sub>n</sub><sub>c</sub><sub>e</sub><sub>n</sub><sub>t</sub><sub>r</sub><sub>a</sub><sub>t</sub><sub>i</sub><sub>o</sub><sub>n</sub> </line><line>of about 1.5 3 10<sup>1</sup><sup>3</sup>/cm<sup>2</sup>. Since the tetramers are deposited into a </line><line>three-dimensional film, and some of them may lose their function- </line><line>ality during the deposition and thereafter, the actual surface </line><line>concentration may be significantly smaller. Assuming that only about </line><line>1% of the tetramers are actually available for binding, the critical </line><line>force per bond, above which a cell cannot be stably bound to the </line><line>surface (Bell 1978), is given by f<sub>c</sub> ’ 6 310NO_UNICODE12 <sub>3</sub><sub>L</sub><sub>n</sub> <sub>(</sub><sub>N</sub><sub>s</sub><sub>/</sub><sub>K</sub><sub>D</sub>(2d)<sub>)</sub> </line><line>’ 35pN/ </line><line>bond, where Ns is the effective surface concentration of the tetramer </line><line>and K<sub>D</sub><sup>(</sup><sup>2</sup><sup>d</sup><sup>)</sup> is the estimated two-dimensional dissociation constant </line><line>between the OT-1 TCR and a single OVA/MHC tetramer (K<sub>D</sub><sup>(</sup><sup>2</sup><sup>d</sup><sup>)</sup>, </line><line>; </line><line>4 <sub>3</sub><sub>1</sub><sub>0</sub><sub>8</sub> <sub>m</sub><sub>o</sub><sub>l</sub><sub>e</sub><sub>c</sub><sub>u</sub><sub>l</sub><sub>e</sub><sub>s</sub><sub>/</sub><sub>c</sub><sub>m</sub><sub>2</sub><sub>)</sub><sub>.</sub> </line><line>For medium viscosity g1⁄47310NO_UNICODE3 <sub>g</sub><sub>/</sub><sub>(</sub><sub>c</sub><sub>m</sub><sub>/</sub><sub>s</sub><sub>)</sub> <sub>a</sub><sub>n</sub><sub>d</sub> <sub>c</sub><sub>e</sub><sub>l</sub><sub>l</sub> <sub>r</sub><sub>a</sub><sub>d</sub><sub>i</sub><sub>u</sub><sub>s</sub> <sub>a</sub> <sub>1⁄4</sub><sub>3</sub> <sub>l</sub><sub>m</sub><sub>,</sub> </line><line>the hydrodynamic Stocks force, F, exerted by a constant flow during </line><line>washout of unbound cells is given by F1⁄46pgat, where t is the velocity </line><line>of the slide as it moves through the washing medium. Hence, for a <sub>t</sub><sub>y</sub><sub>p</sub><sub>i</sub><sub>c</sub><sub>a</sub><sub>l</sub> <sub>w</sub><sub>a</sub><sub>s</sub><sub>h</sub><sub>i</sub><sub>n</sub><sub>g</sub> <sub>v</sub><sub>e</sub><sub>l</sub><sub>o</sub><sub>c</sub><sub>i</sub><sub>t</sub><sub>y</sub> <sub>o</sub><sub>f</sub> <sub>1</sub><sub>0</sub> <sub>c</sub><sub>m</sub><sub>/</sub><sub>s</sub><sub>,</sub> <sub>t</sub><sub>h</sub><sub>e</sub> <sub>d</sub><sub>e</sub><sub>t</sub><sub>a</sub><sub>c</sub><sub>h</sub><sub>i</sub><sub>n</sub><sub>g</sub> <sub>f</sub><sub>o</sub><sub>r</sub><sub>c</sub><sub>e</sub> <sub>F</sub> <sub>1⁄4</sub><sub>4</sub><sub>n</sub><sub>N</sub> <sub>m</sub><sub>a</sub><sub>y</sub> </line><line>be compensated by as few as 114 OT-1/OVA tetramer bonds. </line><line>Assuming an interaction area of 15 lm<sup>2</sup>, the surface concentration </line><line>of bound OT-1 TCRs at the time of washing must be higher than 7.6/ <sub>l</sub><sub>m</sub><sub>2</sub><sub>.</sub> <sub>S</sub><sub>u</sub><sub>c</sub><sub>h</sub> <sub>s</sub><sub>u</sub><sub>r</sub><sub>f</sub><sub>a</sub><sub>c</sub><sub>e</sub> <sub>d</sub><sub>e</sub><sub>n</sub><sub>s</sub><sub>i</sub><sub>t</sub><sub>y</sub> <sub>c</sub><sub>a</sub><sub>n</sub> <sub>b</sub><sub>e</sub> <sub>e</sub><sub>a</sub><sub>s</sub><sub>i</sub><sub>l</sub><sub>y</sub> <sub>a</sub><sub>c</sub><sub>h</sub><sub>i</sub><sub>e</sub><sub>v</sub><sub>e</sub><sub>d</sub> <sub>e</sub><sub>v</sub><sub>e</sub><sub>n</sub> <sub>f</sub><sub>o</sub><sub>r</sub> <sub>a</sub> <sub>u</sub><sub>n</sub><sub>i</sub><sub>f</sub><sub>o</sub><sub>r</sub><sub>m</sub> </line><line>TCR surface distribution. For example, for a T cell of radius a, having </line><line>a uniform TCR distribution, a surface density of 7.6/lm<sup>2</sup> corresponds </line><line>to a total of 382 TCRs. In a typical OT-1 cell, the TCR expression level </line><line>is about two orders of magnitude higher than this lower bound. A </line><line>more realistic scenario of TCR recruitment to the ‘‘artificial </line><line>immunological synapse’’ (resulting in a nonuniform TCR distribu- </line><line>tion) would correspond to an even lower bound. </line><line>Thus, given the relevant physiological and kinetic parameters </line><line>(incorporated into a simplified adhesion model), the major determi- </line><line>nant of cell capture is the surface density, Ns, of functional peptide– </line><line>MHC complexes. For a sufficiently high Ns, the critical force per </line><line>bond, f<sub>c</sub>, is high enough to provide for a stable cell capture with as few </line><line>as a couple hundred peptide–MHC–TCR bonds. Note that the </line><line>logarithmic dependence of the critical force on both the peptide– </line><line>MHC surface concentration and the peptide–MHC–TCR affinity </line><line>(which directly influences the K<sub>D</sub><sup>(</sup><sup>2</sup><sup>d</sup><sup>)</sup>) gives rise to a wide range of Ns </line><line>and K<sub>D</sub><sup>(</sup><sup>2</sup><sup>d</sup><sup>)</sup> values that are compatible with a stable capture. </line><line>Figure S1. Binding of OT-1 Lymphocytes to a Serial Dilution of OVA/ <sub>K</sub><sub>b</sub> <sub>T</sub><sub>e</sub><sub>t</sub><sub>r</sub><sub>a</sub><sub>m</sub><sub>e</sub><sub>r</sub> </line><line>The effect of tetramer dilution on cell capture was tested by </line><line>examining the binding of OT-1 lymphocytes to a serial dilution of </line><line>immobilized OVA/MHC tetramer. The cells were suspended at a </line><line>concentration of 2.5 310<sup>6</sup>/ml and incubated on the array for 30 min </line><line>at room temperature. Following the removal of unbound cells, the </line><line>array was imaged and scored for the number of OT-1 cells on each of </line><line>the spots. </line><line>(A) A reconstruction of the relevant array region by a patchwork of </line><line>103images, revealing a monotonic reduction in the number of bound </line><line>cells with tetramer dilution. Amount of MHC tetramer deposited is </line><line>given in nanograms per spot. </line><line>(B) In this specific example, the number of immobilized OT-1 </line><line>lymphocytes on the OVA/K<sup>b</sup> spots was linearly dependent on the </line><line>amount of tetramer deposited. Averaged cell numbers and standard </line><line>errors are based on triplicate spots. The line represents a linear fit to </line><line>the data. </line><line>View online at DOI: 10.1371/journal/pbio.0000065.sg001 (for Figure </line><line>S1A) (3.89 MB TIFF) and at DOI: 10.1371/jourrnal/pbio.0000065.sg002 </line><line>(for Figure S1B) (5.83 MB TIFF). </line><line>Protocol S1. Online Protocol for the MHC Cellular Microarray </line><line>This protocol serves as a general template for a basic MHC cellular </line><line>microarray experiment. Depending on the exact goal of a specific </line><line>experiment, some of the parameters described may require mod- </line><line>ification. </line><line>View online at DOI: 10.1371/journal/pbio.0000065.sd001 (38 KB </line><line>DOC). </line><line>Acknowledgments </line><line>We would like to thank M. Krogsgaard for supplying the MCC/I-E<sup>k</sup> </line><line>tetramer; J. T. Chi, B. F. Lillemeier, Y. H. Chien, P. J. Ebert, J. B. </line><line>Huppa, M. Krogsgaard, M. S. Kuhns, Q. Li, M. A. Purhboo, and C. </line><line>Sumen for scientific discussions. This study was funded by grants </line><line>from the Howard Hughes Medical Institute, the Human Frontier </line><line>Science Program, the Pediatric Scientist Development Program, and </line><line>the National Institutes of Health. </line><line>Conflicts of interest. The authors have declared that no conflicts of </line><line>interest exist. </line><line>Author contributions. YS and DSC conceived and designed the </line><line>experiments. YS and DSC performed the experiments. YS and DSC </line><line>analyzed the data. YS, DSC, DLK, MMD, and POB contributed </line><line>reagents/materials/analysis tools. YS, DSC, MMD, and POB wrote the </line><line>paper. DLK helped to initially conceive of the work and experiments. </line><line>YS and DSC should be considered co-first authors on this paper. </line><line>MMD and POB suggested ideas and experiments. MMD and POB </line><line>should be considered co-principal investigators and co-correspond- </line><line>ing authors on this paper. <sub>&amp;</sub> </line><line>References </line><line>Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, et al. </line><line>(1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274: </line><line>94–96. </line><line>Bach JM, Otto H, Jung G, Cohen H, Boitard C, et al. (1998) Identification of </line><line>mimicry peptides based on sequential motifs of epitopes derived from 65- </line><line>kDa glutamic acid decarboxylase. Eur J Immunol 28: 1902–1910. </line><line>Bell GI (1978) Models for the specific adhesion of cells to cells. Science 200: </line><line>618–627. </line><line>Belov L, de la Vega O, dos Remedios CG, Mulligan SP, Christopherson RI (2001) </line><line>Immunophenotyping of leukemias using a cluster of differentiation </line><line>antibody microarray. Cancer Res 61: 4483–4489. </line><line>Callan MF, Tan L, Annels N, Ogg GS, Wilson JD et al. (1998) Direct visualization </line><line>of antigen-specific CD8þ T cells during the primary immune response to </line><line>Epstein–Barr virus in vivo. J Exp Med 187: 1395–1402. </line><line>Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, et al. (1998) Ligand </line><line>recognition by alpha beta T cell receptors. Annu Rev Immunol 16: 523–544. </line><line>Eisen MB, Brown PO (1999) DNA arrays for analysis of gene expression. </line><line>Methods Enzymol 303: 179–205. </line><line>Fazekas de St. Groth B, Patten PA, Ho WY, Rock EP, Davis MM (1993) An </line><line>analysis of T cell receptor–ligand interaction using a transgenic antigen </line><line>model for T cell tolerance and T cell receptor mutagenesis. In: Alt FW, </line><line>Vogel AH, editors. Molecular mechanisms of immunological self-recog- </line><line>nition. San Diego, California: Academic Press. pp. 123–127. </line><line>Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffee EM, et al. (1998) Direct </line><line>visualization of antigen-specific T cells: HTLV-1 Tax11–19-specific CD8(þ) T </line><line>cells are activated in peripheral blood and accumulate in cerebrospinal fluid </line><line>from HAM/TSP patients. Proc Natl Acad Sci U S A 95: 7568–7573. </line><line>Haanen JB, van Oijen MG, Tirion F, Oomen LC, Kruisbeek AM, et al. (2000) In situ </line><line>detection of virus- and tumor-specific Tcell immunity. Nat Med6: 1056–1060. </line><line>Hiemstra HS, Duinkerken G, Benckhuijsen WE, Amons R, de Vries RR, et al. </line><line>(1997) The identification of CD4þ T cell epitopes with dedicated synthetic </line><line>peptide libraries. Proc Natl Acad Sci U S A 94: 10313–10318. </line><line>Hiemstra HS, Benckhuijsen WE, Amons R, Rapp W, Drijfhout JW (1998a) A new </line><line>hybrid resin for stepwise screening of peptide libraries combined with single </line><line>bead Edman sequencing. J Pept Sci 4: 282–288. </line><line>Hiemstra HS, van Veelen PA, Schloot NC, Geluk A, van Meijgaarden KE, et al. </line><line>(1998b) Definition of natural T cell antigens with mimicry epitopes obtained </line><line>from dedicated synthetic peptide libraries. J Immunol 161: 4078–4082. </line><line>Hiemstra HS, van Veelen PA, Willemen SJ, Benckhuijsen WE, Geluk A, et al. </line><line>(1999) Quantitative determination of TCR cross-reactivity using peptide </line><line>libraries and protein databases. Eur J Immunol 29: 2385–2391. </line><line>Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, et al. (1994) T cell </line><line>receptor antagonist peptides induce positive selection. Cell 76: 17–27. </line><line>Honeyman MC, Stone NL, Harrison LC (1998) T cell epitopes in type 1 diabetes </line><line>autoantigen tyrosine phosphatase IA-2: Potential for mimicry with rotavirus </line><line>and other environmental agents. Mol Med 4: 231–239. </line><line>PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 437 </line><line>Cellular Peptide–MHC Microarrays </line><line>Ignatowicz L, Kappler J, Marrack P (1996) The repertoire of T cells shaped by a <sub>s</sub><sub>i</sub><sub>n</sub><sub>g</sub><sub>l</sub><sub>e</sub> <sub>M</sub><sub>H</sub><sub>C</sub><sub>/</sub><sub>p</sub><sub>e</sub><sub>p</sub><sub>t</sub><sub>i</sub><sub>d</sub><sub>e</sub> <sub>l</sub><sub>i</sub><sub>g</sub><sub>a</sub><sub>n</sub><sub>d</sub><sub>.</sub> <sub>C</sub><sub>e</sub><sub>l</sub><sub>l</sub> <sub>8</sub><sub>4</sub><sub>:</sub> <sub>5</sub><sub>2</sub><sub>1</sub><sub>–</sub><sub>5</sub><sub>2</sub><sub>9</sub><sub>.</sub> </line><line>Kersh GJ, Allen PM (1996) Structural basis for T cell recognition of altered </line><line>peptide ligands: A single T cell receptor can productively recognize a large </line><line>continuum of related ligands. J Exp Med 184: 1259–1268. </line><line>Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, et al. (1999) Characterization </line><line>of circulating T cells specific for tumor-associated antigens in melanoma </line><line>patients. Nat Med 5: 677–685. </line><line>Mason D (1998) A very high level of crossreactivity is an essential feature of the </line><line>T cell receptor. Immunol Today 19: 395–404. </line><line>Misko IS, Cross SM, Khanna R, Elliott SL, Schmidt C, et al. (1999) Crossreactive </line><line>recognition of viral, self, and bacterial peptide ligands by human class I- </line><line>restricted cytotoxic T lymphocyte clonotypes: Implications for molecular </line><line>mimicry in autoimmune disease. Proc Natl Acad Sci U S A 96: 2279–2284. </line><line>Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, et al. (2000) Evidence </line><line>that specific T lymphocytes may participate in the elimination of chronic </line><line>myelogenous leukemia. Nat Med 6: 1018–1023. </line><line>Muller-Alouf H, Carnoy C, Simonet M, Alouf JE (2001) Superantigen bacterial </line><line>toxins: State of the art. Toxicon 39: 1691–1701. </line><line>Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, et al. (1998a) </line><line>Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load </line><line>of viral RNA. Science 279: 2103–2106. </line><line>Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V (1998b) High </line><line>frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in </line><line>autoimmune vitiligo. J Exp Med 188: 1203–1208. </line><line>Pinilla C, Appel JR, Houghten RA (1994) Investigation of antigen-antibody </line><line>interactions using a soluble nonsupport-bound synthetic decapeptide </line><line>library composed of four trillion sequences. Biochem J 301: 847–853. </line><line>Reay PA, Kantor RM, Davis MM (1994) Use of global amino acid replacements </line><line>to define the requirements for MHC binding and T cell recognition of moth </line><line>cytochrome c (93–103). J Immunol 152: 3946–3957. </line><line>Rosenberg SA (2001) Progress in human tumour immunology and immuno- </line><line>therapy. Nature 411: 380–384. </line><line>Seneviratne SL, Jones L, King AS, Black A, Powell S, et al. (2002) Allergen- </line><line>specific CD8(þ) T cells and atopic disease. J Clin Invest 110: 1283–1291. </line><line>Smith SM, Brookes R, Klein MR, Malin AS, Lukey PT, et al. (2000) Human CD8þ </line><line>CTL specific for the mycobacterial major secreted antigen 85A. J Immunol </line><line>165: 7088–7095. </line><line>Wu ̈ cherpfennig KW, Strominger JL (1995) Molecular mimicry in T cell- </line><line>mediated autoimmunity: Viral peptides activate human T cell clones specific </line><line>for myelin basic protein. Cell 80: 695–705. </line><line>Zhao ZS, Granucci F, Yeh L, Schaffer PA, Cantor H (1998) Molecular mimicry </line><line>by herpes simplex virus-type 1: Autoimmune disease after viral infection. </line><line>Science 279: 1344–1347. </line><line>PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 3 | Page 438 </line><line>Cellular Peptide–MHC Microarrays</line></article>

